New Study Suggests Proactive Filler Treatments May Counter Facial Volume Loss During Weight Loss with GLP-1 Medications
New York, NY – Emerging research indicates that strategically timed injections of a diluted form of the filler Radiesse may help preserve facial volume and skin texture in individuals undergoing weight loss with GLP-1 medications, possibly mitigating the so-called “Ozempic Face.” A recent case series published by researchers suggests a proactive approach – treating before noticeable facial deflation occurs – could be key.
The study, involving four women aged 45 to 54 actively losing weight on GLP-1 medications, followed patients for six months after they received two sessions of hyperdilute Radiesse in the midface and lower face. Participants experienced an average weight loss of 24 pounds, yet 3D imaging revealed their facial support and skin texture were better maintained compared to typical patterns of weight-loss-related hollowing.
“Using 3D imaging, we saw that patients treated with hyperdilute Radiesse maintained better facial support and skin texture during active weight loss with just one syringe per treatment session when applying anatomic precision,” explained Dr. Durairaj, the study’s lead investigator.
Customary Radiesse is a calcium hydroxylapatite filler known for stimulating collagen and elastin production. When “hyperdiluted,” it functions less as a volumizer and more as a regenerative treatment, reinforcing the underlying facial structure with thin threads of filler placed across key support zones in the midface and jawline.
The research highlights the importance of timing. Dr.Durairaj’s team found that initiating treatment early – once a patient is on a stable GLP-1 dose and weight loss has begun – may allow the body’s collagen response to keep pace with volume changes. “This is a proactive facial preservation strategy. Treat early, go low and slow, respect anatomy and reassess as the pounds come off,” she stated.
As hyperdilute Radiesse is not dissolvable like hyaluronic acid fillers, the study emphasizes the need for treatment by an experienced provider with a thorough understanding of facial anatomy and regenerative injectables. While the research is preliminary, with a small sample size, it offers a potential new strategy for GLP-1 patients seeking to minimize facial aging during weight loss.
The findings suggest a shift in perspective, from fixing facial changes associated with GLP-1s to protecting facial structure during weight loss, offering reassurance that facial aging doesn’t necessarily have to be a side effect of medication-assisted weight management.
